Drawing for NEURIMMUNE

USPTO serial 87819026

NEURIMMUNE

Reviewed by CopyMark Law Group

Reg. 6197817Status 700Renewal
Filing date
Status date
Registration date
Nov 17, 2020
Examiner
HILL, JAMES T
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with NEURIMMUNE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*

Plus Government fees of $975

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Janice Housey

4 Weems Lane #240Winchester, VA 22601United States

Goods and services

ClassDescriptionStatusFirst use
005pharmaceutical preparations for treating diseases of the nervous system, infectious diseases, neoplasms, diseases of the immune system, endocrine and metabolic diseases, diseases of the circulatory system, diseases of the eye; veterinary preparations for treating diseases of the nervous system, infectious diseases, neoplasms, diseases of the immune system, endocrine and metabolic diseases, diseases of the circulatory system, diseases of the eye; pharmaceutical preparations for immunotherapeutic purposes; pharmaceutical agents for the removal of tumors; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations, namely, immunogens; pharmaceutical preparations, namely, antibodies for use in disease testing; vaccines; diagnostic preparations for medical purposes in the form of epitopes for detection of anomalies in proteins; pharmaceutical preparations, namely, synthetic peptides for use in the treatment of diseases of the CNS, metabolic diseases, cardiovascular diseases, cancer, psychiatric diseases, infections; sanitary preparations for medical use; biological pharmaceutical and veterinary preparations for medical use being for the treatment of diseases of the CNS, metabolic diseases, cardiovascular diseases, cancer, psychiatric diseases, infections; pharmaceutical and veterinary biocides; diagnostic preparations for medical and veterinary purposes; sanitary towels for hygiene purposes; dietetic foods adapted for medical use; dietetic beverages adapted for medical use; biological pharmaceutical and veterinary preparations in the nature of protein antibodies targeting specific epitopes of proteins for use in the treatment of diseases of the CNS, metabolic diseases, cardiovascular diseases, cancer, psychiatric diseases, infections, immunologic diseases, inflammatory diseases, respiratory diseases, psychological diseases for medical purposes; antibacterial pharmaceutical and veterinary preparations, namely, antibacterial substances for medical purposes, antibacterial pharmaceuticals; biopharmaceutical preparations for the treatment of cancer; protein dietary supplementsACTIVE—
042monitoring, inspection, and analysis of biologically active chemical substances for quality control purposes; research on pharmaceutical products, cosmetics and foodstuffs for others; consultancy and information services in the field of monitoring and inspection for the quality control and analysis of biologically active chemical substances; research in the field of medical treatment and methods; research in the fields of biotechnology and antibodies; medical and scientific research information in the field of clinical trial testing and research in medical treatment; research in the field of sanitary care; monitoring and inspection of biological synthesis and pharmaceutical manufacturing for quality control and scientific research purposes and research in the field of biology; computer software design; computer programming; maintenance of computer software; design and development of computer hardware; development of computer software; consultancy and provision of information relating to quality control of pharmaceutical preparations; scientific research in the field of cancerous diseases; scientific research relating to chemistryACTIVE—
044medical services; medical services in the field of immunity; provision of medical information; medical examinations, namely, physical examination for medical purposes; preparation of medicines, namely, pharmaceutical compounding services and dispensing of medicines in the nature of pharmaceuticals; healthcare services in the nature of nutritional and dietary consultancy; consultancy and provision of information in the field of sanitary care, namely, providing sanitary health care information; veterinary services; beauty salon services; care services for animals, namely, veterinary care services; hygienic care; consultancy and provision of medical information relating to the operation, preparation, administration and dosage of pharmaceutical preparations; advisory services relating to pharmaceuticals; providing medical information to healthcare professionals and patients in the form of compiled medical reports in the field of diagnostic, prophylactic and therapeutic properties of pharmaceuticals; drug use screening services for medical purposes; information services relating to health careACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 17, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 19, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 19, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 19, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 12, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 12, 2025ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
May 12, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 12, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 12, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 12, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Nov 10, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 10, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 10, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 21, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jan 21, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 21, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 21, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 21, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jul 21, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 21, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jul 21, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 21, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Nov 17, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 1, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 1, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 12, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 27, 2020CNEAEXAMINERS AMENDMENT MAILED—
Jul 27, 2020XAAPEXAMINER'S AMENDMENT AFTER PUB APPROVAL—
Jul 14, 2020OTHECASE RETURNED TO EXAMINATION—
Jul 14, 2020IUCNNOTICE OF ALLOWANCE CANCELLED—
Jul 2, 2020ATRQATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED—
Jul 2, 2020PCBGPETITION TO DIRECTOR - CHANGE BASIS - GRANTED—
Jul 2, 2020APETASSIGNED TO PETITION STAFF—
Jul 2, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jul 2, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
May 26, 2020EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
May 26, 2020TPADTEAS PETITION TO AMEND BASIS RECEIVED—
Apr 21, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 18, 2020EX3GSOU EXTENSION 3 GRANTED—
Apr 18, 2020EXT3SOU EXTENSION 3 FILED—
Apr 18, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 3, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 1, 2019EX2GSOU EXTENSION 2 GRANTED—
Oct 1, 2019EXT2SOU EXTENSION 2 FILED—
Oct 1, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 13, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 11, 2019EX1GSOU EXTENSION 1 GRANTED—
Apr 11, 2019EXT1SOU EXTENSION 1 FILED—
Apr 11, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 30, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 4, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 4, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 15, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 27, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 27, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Jul 27, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 27, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 27, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 16, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 15, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 15, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 22, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 22, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 22, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 15, 2018DOCKASSIGNED TO EXAMINER—
Mar 10, 2018MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Mar 9, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 7, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance